Jianpi Huazhuo Formula Suppresses Choroidal Neovascularization by Modulating the AKT1/MAPK3/IL6 Axis.
- 1Senior Department of Ophthalmology Chinese PLA General Hospital Beijing China 301hospital.com.cn.
Abstract
This study elucidates the therapeutic mechanisms of Jianpi Huazhuo formula (JHF) in suppressing laser-induced choroidal neovascularization (CNV) through the modulation of the AKT1/MAPK3/IL6 signaling pathway. Utilizing a murine CNV model, JHF administration markedly attenuated vascular leakage, as evidenced by fluorescein angiography, optical coherence tomography, and fundus imaging. Integrated network pharmacology pinpointed AKT1, MAPK3, and IL6 as pivotal targets, with functional enrichment analyses highlighting their roles in key processes such as reactive oxygen species response and inflammatory regulation, particularly within the PI3K-Akt and IL-17 pathways. Molecular docking validated robust interactions between JHF-derived compounds (e.g., luteolin and quercetin) and these targets, exhibiting binding energies ranging from -4.0 to -7.41 kcal/mol. Subsequent molecular assays confirmed that JHF significantly reduced AKT1, MAPK3, and IL6 expression at transcriptional and translational levels in RPE-choroid tissues. Time-dependent expression profiling further revealed sustained suppression of these targets throughout CNV progression, and in vitro validation in an oxidative stress-induced ARPE-19 cell model confirmed the direct regulatory effect of JHF on this signaling axis. These findings demonstrate that JHF exerts its antiangiogenic effects via a multitarget network centered on the AKT1/MAPK3/IL6 axis. The study innovatively delineates JHF's polypharmacological mode of action, offering novel insights for leveraging traditional Chinese medicine in managing neovascular ocular diseases.
Related
- A Case of Punctate Inner Choroidopathy in the Fellow Eye Followed by the Development of Solitary Punctate Chorioretinitis With Choroidal Neovascularization.
- Xifenghuashi formula ameliorates diarrhea predominant-irritable bowel syndrome by modulating the gut microbiota and the bile acid-FXR-FGF axis: A human trial and an animal experiment
- Benzoylaconine suppresses colorectal cancer progression by modulating the CDK2/MMP2 signaling axis
- ZRANB1-mediated EZH2 stabilization drives S100B/S100A4 transcriptional activation and corneal neovascularization in alkali burns.
- Efficacy and durability of GB10, a novel bispecific VEGF/Ang-2 neutralizing fusion protein, in ocular neovascularization models
BibTeX
@article{yang2026jianpi,
title = {{Jianpi Huazhuo Formula Suppresses Choroidal Neovascularization by Modulating the AKT1/MAPK3/IL6 Axis.}},
author = {Liu Yang and Shuqi Zhang and Cui Han},
journal = {Journal of ophthalmology},
year = {2026},
month = oct,
doi = {10.1155/joph/5529488},
url = {https://europepmc.org/article/MED/42921545},
note = {CC BY},
}
RIS
TY - JOUR
TI - Jianpi Huazhuo Formula Suppresses Choroidal Neovascularization by Modulating the AKT1/MAPK3/IL6 Axis.
AU - Liu Yang
AU - Shuqi Zhang
AU - Cui Han
PY - 2026
DA - 2026/10/23
JO - Journal of ophthalmology
DO - 10.1155/joph/5529488
UR - https://europepmc.org/article/MED/42921545
AB - This study elucidates the therapeutic mechanisms of Jianpi Huazhuo formula (JHF) in suppressing laser-induced choroidal neovascularization (CNV) through the modulation of the AKT1/MAPK3/IL6 signaling pathway. Utilizing a murine CNV model, JHF administration markedly attenuated vascular leakage, as evidenced by fluorescein angiography, optical coherence tomography, and fundus imaging. Integrated network pharmacology pinpointed AKT1, MAPK3, and IL6 as pivotal targets, with functional enrichment analyses highlighting their roles in key processes such as reactive oxygen species response and inflammatory regulation, particularly within the PI3K-Akt and IL-17 pathways. Molecular docking validated robust interactions between JHF-derived compounds (e.g., luteolin and quercetin) and these targets, exhibiting binding energies ranging from -4.0 to -7.41 kcal/mol. Subsequent molecular assays confirmed that JHF significantly reduced AKT1, MAPK3, and IL6 expression at transcriptional and translational levels in RPE-choroid tissues. Time-dependent expression profiling further revealed sustained suppression of these targets throughout CNV progression, and in vitro validation in an oxidative stress-induced ARPE-19 cell model confirmed the direct regulatory effect of JHF on this signaling axis. These findings demonstrate that JHF exerts its antiangiogenic effects via a multitarget network centered on the AKT1/MAPK3/IL6 axis. The study innovatively delineates JHF's polypharmacological mode of action, offering novel insights for leveraging traditional Chinese medicine in managing neovascular ocular diseases.
SN - 2090-004X
SN - 2090-0058
ER -